Introduction {#Sec1}
============

Radioembolization (RE), also known as selective internal radiation therapy (SIRT) or transarterial RE (TARE), is a promising therapy in both safety and efficacy aspects for non-resectable primary and metastatic liver malignancies \[[@CR1]--[@CR5]\] which is recommended in guidelines in the salvage setting in metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC) when other therapies are contraindicated or have failed, and for small tumors in patients waiting for liver transplantation \[[@CR6], [@CR7]\]. Several large randomized trials have investigated SIRT in HCC and mCRC and did not meet their primary endpoint, highlighting the need for optimization of the technique and patient selection \[[@CR1], [@CR2], [@CR8]--[@CR11]\].

In SIRT, millions of implantable microspheres containing yttrium-90 (^90^Y) are administrated into the hepatic artery during a femoral arterial catheterization \[[@CR12], [@CR13]\] which results in higher concentration in the tumors located within that liver perfusion territory than within the normal liver parenchyma \[[@CR14]\].

Before injecting the ^90^Y microspheres, a simulation is performed in which the patient-specific vascular anatomy is determined and specific arteries are coiled to prevent extra-hepatic dissemination \[[@CR15]\]. Then, macro-aggregated albumin (MAA) particles labeled with technetium-99m (^99m^Tc) are injected, and within the hour after injection, a scintigraphic planar imaging and single-photon emission-computed tomography with X-ray computed tomography (SPECT/CT) are performed \[[@CR16]\]. These images are used to quantify a possible pulmonary shunt and determine extra-hepatic uptake. These SPECT/CT images can be used to predict the intrahepatic distribution of the ^90^Y spheres as well, enabling a pre-therapeutic dosimetric analysis. Subsequently, the patient undergoes a second procedure in which a prescribed amount of ^90^Y spheres are injected. ^90^Y is a beta emitter. In soft tissue, 2.23% of the electrons produce a bremsstrahlung photon with an energy of 50 keV or more. Its decay also has a very small positron branching ratio (32 per million decays) \[[@CR17], [@CR18]\]. Therefore, the actual distribution of the spheres can be determined by bremsstrahlung emission-computed tomography or time-of-flight positron emission tomography (PET) \[[@CR19]--[@CR21]\].

Because of the high kinetic energy of the emitted electrons (mean energy of 0.934 MeV, mean and maximum tissue penetration of 2.5, and 11 mm, respectively), treatment with ^90^Y resin microspheres can achieve an absorbed dose (the energy that will be absorbed per unit of tissue mass) of about 100 to 1000 Gy to the tumor which is sufficient for complete tumor ablation, while keeping the healthy tissue irradiation below the safety threshold (typically in the order of 30--50 Gy) \[[@CR22], [@CR23]\]. Estimating the absorbed dose to the tumor(s) and the normal liver parenchyma has a key role in radionuclide therapy for predicting the tumor response and healthy liver toxicity \[[@CR24]\].

The so-called partition method is a tissue level dosimetry method that is used widely as a tool to predict mean absorbed dose in the tumor and healthy liver. This method assumes uniform activity in tumor and normal liver compartments \[[@CR25]\]. However, there are some concerns about using the mean absorbed dose in SIRT because of the inherent activity heterogeneity. For this reason, using a more detailed dosimetry is vital for treatment optimization \[[@CR8], [@CR26]\]. The role of MAA-based dose estimation for a safe normal parenchyma absorbed dose and efficient tumor absorbed dose has been investigated in several studies \[[@CR27]--[@CR29]\]. Post-treatment dosimetry has also been studied to verify the treatment planning \[[@CR30]--[@CR33]\].

Recent arguments over choosing between an activity prescription based on body surface area (BSA) and dosimetry-based prescription in the treatment planning procedure \[[@CR34], [@CR35]\] accentuate the relevance of quality control, dosimetry process verification, and standardization in the field of SIRT. In addition to the activity distribution estimation uncertainties (e.g., simulating power of MAA, partial volume effect, breathing motion), some errors are introduced by image processing techniques, e.g., image registration and segmentation, which need to be avoided \[[@CR8]\]. To date, activity calculation based on BSA is used for SIRT with resin microspheres in one third of European hospitals regardless of availability of numerous commercial softwares designed for dosimetry \[[@CR36], [@CR37]\]. This is possibly due to lack of image processing validation, error estimation, or complexity of the process and regulation.

Image registration accuracy has been investigated for CT to CT liver registration for contrast-enhanced diagnostic CTs \[[@CR38]\]. Over the past decade, numerous semi-automatic and automatic approaches for liver segmentation \[[@CR39], [@CR40]\] on CT that rely on histogram-based methods \[[@CR41], [@CR42]\], graph cut \[[@CR43]--[@CR45]\], region growing \[[@CR45]--[@CR47]\], geometric deformable model and level set \[[@CR48]--[@CR50]\], probabilistic atlas \[[@CR51], [@CR52]\], statistical shape models \[[@CR53]--[@CR55]\], and recently neural network \[[@CR56]--[@CR59]\] have been proposed. Despite these efforts, image registration and segmentation remains a challenging task for SIRT application for several reasons: (1) liver is a soft tissue and liver shape is heavily dependent on patient positioning (e.g., the position of the arms); (2) the liver shape in SIRT patients differs from the normal shape, because of preceding treatments (liver resection, liver ablation, chemotherapy) and tumor growth which makes it challenging to use liver segmentation techniques which are dependent on the liver shape for these patients; (3) liver is a soft tissue and its Hounsfield units are similar to those of adjacent organs like the heart, spleen, stomach, and kidney, which makes liver segmentation on non-contrast-enhanced CTs (e.g., CT from MAA study) hard, even for experts; (4) CT from MAA study is not a dedicated diagnostic CT, this low-dose CT usually suffers from streak artifacts; and (5) the interval between the MAA study and the diagnostic high-dose, contrast-enhanced CT from from fluorine-18 fluorodeoxyglucose (^18^F-FDG) PET/CT study can be up to weeks to even 1 or 2 months and the liver can deform dramatically over time for several reasons, e.g., tumor change.

Although liver segmentation techniques offer highly accurate results for healthy liver on contrast-enhanced CTs, few studies applied volumetric methods to the baseline and/or non-contrast-enhanced, low-dose CTs for radiation therapy planning. Monsky et al. propose a method based on iterative watershed segmentation to semi-automatic volumetric segmentation of the liver, tumor, and necrosis using multiphase CTs in 14 patients. They compare their results with manual liver segmentation and report a good interobserver/intraobserver reproducibility \[[@CR60]\]. Goryawala et al. present a framework for extracting a 3D liver segmentation based on coupling a *k*-mean algorithm with a localized contouring method. They applied their method to 5 patients aiming at minimizing human intervention \[[@CR61]\]. In \[[@CR62]\], and they improved their method by decreasing the human intervention time and applying their workflow to 34 patients with liver metastatic.

To overcome the inaccuracy of liver segmentation due to the similar Hounsfield values of the liver and its surrounding organs in non-contrast-enhanced CTs, some studies use co-segmentation algorithm, using information from different co-registered modalities (e.g., PET and CT) to guide the liver segmentation. Wang et al. use ^18^F-FDG uptake difference between the liver and adjacent organs to separate them for 12 patients \[[@CR63]\]. Later, they apply their method to more patients \[[@CR64]\] and using probabilistic atlas \[[@CR65]\]. Mendes et al. present a framework for outlining liver using CT alone, PET alone, and a hybrid modality liver segmentation using information from PET and CT together \[[@CR66]\].

The main aim of this study is to develop a multi-modal image analysis approach that can be used for voxel level and partition model dosimetry, using pre-treatment simulation based on the ^99m^Tc-MAA study. This methodology is generic and can be extended for post-treatment dose verification images. For this purpose, we developed and evaluated a new methodology for image registration, for liver segmentation using all pre-therapy image data, for ^18^F-FDG tumor segmentation using ^18^F-FDG PET/CT, and for liver perfusion territory (LPT) segmentation using the cone beam CT (CBCT).

To our best knowledge, this is the first attempt to investigate the role of lobe segmentation based on contrast-enhanced CBCT for dosimetry and activity prescription. LPTs are usually segmented using the anatomical landmarks on CT, which reflect the standard anatomical venous lobe segmentation \[[@CR67]\]. In our hospital, contrast-enhanced CBCT is acquired in the early and late arterial phase during the angiographic work-up to outline the different LPTs \[[@CR68], [@CR69]\].

To our knowledge, there are no reported studies investigating the registration accuracy for SIRT therapy planning; CBCT and low-dose, non-contrast-enhanced CT registration. We are also implementing a multi-model liver segmentation approach which uses the ^18^F-FDG-PET/CT aligned to the CT from the MAA-SPECT/CT study. The current version is still semi-automatic, and its preliminary evaluation shows that it produces a segmentation similar to that produced by an expert operator on the contrast-enhanced CT using commercial software. Nevertheless, we present the method already here because we believe that such a multi-modal segmentation approach has the potential to improve the segmentation of the liver and the tumor lesions. Details about the method are provided as supplementary material.

The paper is organized as follows: In the "[Methods and materials](#Sec2){ref-type="sec"}Methods" section, the multi-modal image analysis algorithm is described: first, all images are registered to the same space, then the liver, the LPTs and the tumors are delineated. Then, the results of the proposed algorithm are shown and compared to a manual segmentation by an expert in the "[Results](#Sec18){ref-type="sec"}" section. Finally, in "[Discussion](#Sec25){ref-type="sec"}" section, our results are discussed. In the "[Conclusion](#Sec31){ref-type="sec"}" section, some conclusions are presented and some future directions are discussed.

Methods and materials {#Sec2}
=====================

Patient selection {#Sec3}
-----------------

Between May 2014 and December 2017, 22 consecutive patients underwent bilobar SIRT in the University Hospitals Leuven (UZ Leuven, Leuven, Belgium) with early and late arterial phase CBCT imaging for both lobes before treatment (for delineating different LPTs) and with ^18^F-FDG PET/CT imaging (for delineating ^18^F-FDG avid malignancies). Of these, 5 patients were excluded from the study due to artifacts or low-image quality in the MAA SPECT/CT study (*n* = 3), CBCT images (*n* = 1) and ^18^F-FDG PET/CT study (*n* = 1). Pre- and post- treatment images were collected and analyzed retrospectively. From these patients, a set of 7 patients with a HCC, 2 breast, 2 melanoma, a colorectal, and an esophageal cancer was arbitrarily selected to optimize the parameters of the algorithm (so-called "training set") and 10 patients, 6 colorectal cancer, an esophageal cancer, a neuroendocrine tumor, a colon cancer, and a cholangiocellular cancer were used for an independent evaluation (so-called "test set"). Detailed patient characteristics are provided in the Appendix.

Pre-treatment studies {#Sec4}
---------------------

Pre-treatment studies were performed for SIRT (see Fig. [1](#Fig1){ref-type="fig"}) based on the European Association of Nuclear Medicine (EANM) guideline \[[@CR70]\], the recommendations of the American Association of Physics in Medicine (AAPM) \[[@CR13]\], and the SIRTEX manual \[[@CR71]\]. Fig. 1Single transaxial slice of radioembolization pre-treatment studies and segmentation result (patient ID BI01 from training set in our database): **a** the CT and activity image of the ^99m^Tc-MAA SPECT/CT scan. Correction for scatter and attenuation is applied and a phantom-based calibration factor is used to obtain images of absolute ^99m^Tc concentration \[kBq/cc\]. **b** CBCT images with contrast enhancement facilitating delineation of the right and left liver lobe. **c** The CT and PET of the ^18^F-FDG PET/CT study. **d** The segmented liver, tumor, and LPTs

For a SIRT simulation, about 150 MBq of ^99m^Tc-MAA was infused into the hepatic artery at the position where the therapeutic activity was expected to be administered (about 100 and 50 MBq to the vessels that feed right and left LPTs, respectively). A SPECT/CT was performed as soon as possible \[[@CR16]\], typically within 1 h on a Symbia T16 camera (Siemens Healthineers, Erlangen, Germany).

SPECT, using a dual-head gamma camera, was performed with rotation over 180 °, 60 views per detector, and 21 s per view in a 128 ×128 matrix with 15% energy window centered at the photopeak of ^99m^Tc (140 kev) using low-energy high-resolution collimators. The reconstruction was done using the ordered subset expectation maximization (OSEM) algorithm accounting for attenuation, position-dependent collimator blurring, and a scatter contribution, which was estimated using a dual-energy scatter window. Phantom experiments were done to determine the calibration factor (producing a system sensitivity of 11.7 cpm/kBq), which absolutely quantifies the reconstruction of the images, these results are in line with results provided by Zeintl et al. \[[@CR72]\]. This image was reconstructed with an isotropic voxel size of 4.8 mm. The CT scan (120 mAs, 110 kV) was acquired with 0.9 mm in plane voxel size and 1.0-mm slice thickness.

During the angiographic work-up, contrast-enhanced CBCTs were acquired in the early and late arterial phase, outlining the LPTs of the hepatic artery branches. CBCTs were performed using XtraVision (Philips Healthcare, Amsterdam, Netherlands). These images are not mentioned in the guidelines and there are not many centers that acquire these images as part of the SIRT procedure.

For some patients (e.g., patients with ^18^F-FDG-avid tumors), a whole body ^18^F-FDG PET/CT with a Biograph 40 TruePoint TrueV system (Siemens Healthineers, Erlangen, Germany) was performed up to 2 months before treatment to provide the tumor metabolic data. CT imaging was done mostly with intravenous contrast enhancement for outlining the total liver and the liver tumor burden (85 mAs, 120 kV, plane voxel size of 0.98 mm, slice thickness of 1.5 mm). The PET images were reconstructed using resolution recovery, attenuating and scatter correction, and voxel size, and slice thickness are 2.9 and 5 mm respectively.

SIRT procedure {#Sec5}
--------------

SIR-Spheres (SIRTEX Medical Ltd., Sidney, Australia) were used in all patients. According to the resin microspheres' manufacturer guideline (SIRTEX Medical Ltd., Australia, NSW), determination of therapeutic activity was based on the BSA method \[[@CR71]\] or a one-compartment partition model aiming at keeping the dose to each lobe below 40 to 50 Gy \[[@CR73]\]. The activity was adjusted to have a lung absorbed dose below 30 Gy. The calculated activity was administered according to the manufacturer recommendation \[[@CR71]\].

Image processing {#Sec6}
----------------

We proposed a multi-modal image analysis approach for registering all pre-treatment images to an identical space. These aligned images were used for semi-automatic total liver, tumor, and LPT delineation. All codes were written in-house using IDL 8.4 (Harris Geospatial Solution, Boulder, CO, USA).

Before registering all images to an identical space, a box was defined manually for each image which contains the entire liver; this makes the whole procedure faster and also gives a data reduction for the image registration and segmentation. To define the box for each image, the first and the last plane that contain the liver were selected in each of the three orthogonal views (6 planes). Then, the images were cropped by these boxes, and the cropped images were used in the entire work flow (see Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Patient ID BI01 from training set in our database: **a**, **b** transaxial and coronal view of a CT~MAA~, **c**, **d** median filter and Gaussian filter (fwhm = 4) of the same slide in transaxial slice (image **c**is sharper and voxels within the liver are more homogeneous; red contours show the boxes that are defined for data cropping)

To suppress the noise and increase the voxel intensity homogeneity within the liver, which is helpful for image registration and segmentation, the CT and CBCT images were filtered by three consecutive 2D median filtering with a width of 3 by 3 voxels in all three dimensions. This filter better preserves the organ's edges than Gaussian filtering (see Fig. [2](#Fig2){ref-type="fig"}). The smoothed images were used as an intermediate for segmentation and registration, and the unsmoothed images were also processed in each step.

### Image registration {#Sec7}

The aim is to have all images in an identical space, and we refer to the resulting set of aligned images as the meta-image. Image registration was done in two steps:

First, early and late CBCTs for each LPT were aligned by a rigid registration. This multi-resolution registration used the sum of square differences as the cost function. After registration, averaging over all CBCTs creates an image which covers a larger field of view than the individual CBCTs, because each image is typically focused on a single liver lobe. We refer to this image as meta-CBCT. In addition, the contrast enhancement is suppressed due to averaging which helps further registration.

Then, the meta-CBCT and CT from the ^18^F-FDG study (CT~FDG~) images were registered to the CT from the MAA study (CT~MAA~) non-rigidly (starting from a initial rigid registration), and the PET image was deformed with the deformation obtained for the corresponding CT image. CBCT images were acquired in breath hold. ^18^F-FDG-PET/CT and MAA SPECT/CT imaging allowed shallow breathing. Consequently, breathing impact is unavoidable \[[@CR74]\]. These images were acquired in clinical routine and were not gated for respiratory movement. So, in this study, breathing motion is part of the uncertainties.

The multi-resolution non-rigid registration was done with the algorithm described in \[[@CR75]\]. Mutual information was used as the cost function. This algorithm represented the deformation with a displacement vector in every voxel. The deformation was constrained by assuming that neighboring voxels are connected by nonlinear springs, which can have different rigidity for voxels belonging to different classes. The image was segmented by thresholding into the air, liver, other soft tissues, and bone. The rigidity of the liver was set to a relatively high value, while that of all other tissues was set to a low value. This was done to ensure that the liver registration is good and as rigid as possible and that it is not hindered by alignment of the other structures surrounding the liver. Moreover, the registration is mostly driven by the high-intensity gradients near the liver boundaries. By favoring rigidity, a useful alignment for structures inside the liver can be obtained. Indeed, the perfusion and ^18^F-FDG uptake will not always be matched, and identifying mismatches is highly relevant for treatment planning/verification (see Fig. [1](#Fig1){ref-type="fig"}). The CBCTs and CT~MAA~ acquisitions were within hours from each other with minimal organ change in between.

### Evaluation of registration methodology {#Sec8}

#### Expert evaluation: {#Sec9}

To evaluate CT~FDG~ to CT~MAA~ non-rigid registration, an expert (CMD) scored the results by using a 5-point Likert method. The co-registered datasets were displayed in an orthogonal viewer with transverse, coronal, and sagittal sections and were scored by using these predefined categories: Major misalignment; major impact on dosimetry, dosimetry results not reliablePronounced misalignment; substantial impact on dosimetry is expectedModerate misalignment; little impact on dosimetry is expectedLittle misalignment; no significant impact on dosimetry is expectedNear perfect alignment; no intervention warranted and dosimetry deemed reliable

The following positions were inspected using a cursor point consisting of intersecting orthogonal lines: Cranial, caudal, lateral, and medial most extreme positions of the liver contourThe hilar fat at the portal bifurcationThe ligamentum falciformeThe gallbladder bedInlying calcifications in the liver (most often due to calcified liver metastasis), if presentLiver metastasis if visible on the non-contrast-enhanced CTBiliary cysts, if presentCoils in hilar vascular structures from pre-SIRT work-up, if present

#### Local volume change: {#Sec10}

The liver is assumed to be a non-compressible organ. One can consider the healthy tissue/tumor volume changes over time owing to the time difference between the ^18^F-FDG and ^99m^Tc-MAA study, but still we assumed that local volume changes should be small and could be used as a metric in the evaluation of the registration results.

We used the Jacobian determinant \[[@CR76], [@CR77]\] to evaluate to which extent CT~FDG~ to CT~MAA~ registration was locally volume preserving in three different volumes of interest (VOIs) for each patient: the entire liver, excluded liver, and eroded liver. For the entire liver, the Jacobian of the voxels belonging to the manual liver segmentation was analyzed. For the eroded liver, the manual liver segmentation eroded by a 10-mm kernel was used and the excluded liver was defined as the entire liver subtracted by the eroded liver.

The most obvious feature of the liver used by the registration algorithm is its boundary, in particular for non-contrast-enhanced CT images. The Jacobian is computed in a region near the liver boundary to evaluate the balance between rigidity and similarity ("excluded liver"). In non-contrast-enhanced CT images, the center of the liver contains very few features, and the deformation in the center is mostly driven by the deformation of the boundaries and the rigidity constraint. To evaluate the propagation of the deformation to the center of the liver, the Jacobian is also computed in the central part ("eroded liver").

### Image segmentation {#Sec11}

To define all the VOIs needed for the dosimetry report, one needs to delineate the entire liver, the tumors, and the different liver perfusion territories. All the variables which were used for the liver, tumor, and LPT segmentation and validation are listed in Table [1](#Tab1){ref-type="table"}. Table 1List of variables that are used in VOI segmentation and validationStepVariableDescriptionTumor segmentationTHR (init)Initial threshold of FDG uptake for tumor core definitionTumor segmentationBG (*T*~*i*~)Measured background of tumor *i*Tumor segmentationmax (*T*~*i*~)Measured maximum FDG uptake of tumor *i*Tumor segmentationTHR (*T*~*i*~)Final threshold for tumor *i*Liver evaluationDICEDice coefficientLiver evaluationTPRTrue positive ratio (sensitivity)Liver evaluationPPVPositive prediciton valueLiver evaluationRVRelative volumeLiver/LPT evaluationaHDAverage Hausdorff distanceLiver/LPT evaluationmHDMaximum Hausdorff distanceLPT evaluationVdiffVolume differenceLPT evaluationRratio, LratioRight and left volume ratio

**Liver segmentation:** The entire liver was segmented by a joint region growing by using information from three co-registered images at the same time (CT~MAA~, CT~FDG~, and the ^18^F-FDG PET). This procedure benefits from co-segmentation; the liver is segmented based on the low-dose and low-quality CT from MAA study which is the most important pre-treatment study, but information from ^18^F-FDG study also helps the algorithm to have better initial liver segmentation and smoother manual modification by the expert. Details about liver segmentation are provided as supplementary material (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Semi-automatic liver segmentation steps (patient ID BI01 from training set in our database), **a** manual liver segmentation in every 15th slices, **c** a layer and **b**, **d** transverse slice of the upper and the lower plane of a sample layer and their manual segmentation, **e**, **f** the layer region growing seed (red) and mask (green), **g** a slice in the middle of the layer and its seed and mask, **h** initial region growing result, and **i** final segmentation

**Tumor segmentation:** An adaptive thresholding method was used for tumor segmentation. This method is very similar to the fixed threshold level, but the threshold level is calculated from the tumor-specific background and tumor max SUV \[[@CR78], [@CR79]\]. First, the ^18^F-FDG PET image was converted to SUV values. Then, a mean (*μ*) and standard deviation (*σ*) were computed within the liver. To find the tumor cores, an initial threshold (THR(init)) was set to (confidence interval of 99.5% corresponding to 2.802 sigmas): $$\documentclass[12pt]{minimal}
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Then, each of the detected tumor cores was independently processed to yield a final tumor volume. A mask was generated for each tumor core (*T*~*i*~) after dilation with a uniform sphere of radius 25 mm. The background for *T*~*i*~ (BG(*T*~*i*~)) was defined as the mean value of all voxels in the mask that had an SUV of less than 2.5, the tumor-specific threshold (THR(*T*~*i*~)) was defined as \[[@CR78]\] (see Fig. [4](#Fig4){ref-type="fig"}): Fig. 4Tumor segmentation steps for one of the tumors (patient ID BI01 from training set in our database) that is visible in the slice by using the method proposed in \[[@CR78]\]. For the other tumor(s), the same algorithm was used **a** initial ^18^F-FDG PET and (liver segmentation: green), **b**^18^F-FDG initial threshold and finding initial tumor burden (liver segmentation, green ; tumor cores, red), **c** finding specific background for each tumor (liver segmentation, green; tumor cores, red; background, blue), and **d** final tumor thresholding (liver segmentation, green; initial tumor volume which is not included in the final tumor segmentation, red; final tumor segmentation, blue) $$\documentclass[12pt]{minimal}
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**Perfusion territory segmentation:** The task is to separate the left and right LPT based on the contrast enhancement in the early or late arterial phase of the CBCT. To segment the liver in two lobes, an expert drew lines in at least 3 different transverse slices, then a plane was fit to these lines by using the least square method. The plane was reviewed by the same expert in all 4 sets of CBCTs and revised when needed (see Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Perfusion territory segmentation (patient ID BI01 from training set in our database): **a**, **b** CBCTs with late contrast enhancement for the right and left liver perfusion territory, respectively, **c** difference between two CBCTs, **d** LPT segmentation result (right lobe, blue; left lobe, green)

### Liver segmentation comparison and validation {#Sec15}

A second segmentation of the liver by an expert (WC) on a single contrast-enhanced CT was used to validate our segmentation methodology. This manual segmentation was done using Siemens Syngo MMWP Volume software \[[@CR80]\].

Our segmentation results were compared to those obtained by manual segmentation using dice coefficient, true positive ratio (TPR) or sensitivity, positive predictive value (PPV), relative volume (RV), average Hausdorff distance (aHD), and maximum Hausdorff distance (mHD). Dice coefficient is the most used method to evaluate volume overlapping, TPR shows the ratio of the gold standard that is covered by our segmentation, PPV shows the fraction of our segmentation that is covered by the gold standard, RV reports the volume ratios, and mHD and aHD are based on distances between the boundaries of the two segmentations \[[@CR81], [@CR82]\].

Dice index, TPR, PPV, RV, aHD, and mHD between a volume A and the gold standard segmentation B are given by: $$\documentclass[12pt]{minimal}
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Here, S(X) denotes the set of surface voxels of X and ∥.∥ is the Euclidean distance in mm.

### Impact of using the CBCT images instead of the CT image for defining LPT {#Sec16}

To evaluate our methodology to delineate LPTs of different branches of the hepatic artery (left and right hepatic artery in our patient selection), a second segmentation was done on a single CT by defining a plane to cut the CT for segmenting two different LPTs by using the anatomical landmarks. To manually segment the liver in two lobes, the expert (WC; who performed lobe segmentation on CBCT) segmented the LPTs on the CT images with the same tool that has been used to segment them on the CBCT images. To avoid bias, the expert segmented the LPTs on CT 2 weeks after CBCT-based LPT segmentation. Then, this separation plane was used to define different LPTs by using the transformed liver segmentation.

The VOI for the left and right LPT were compared by using volume difference (Vdiff), left LPT volume ratio (Lratio), right LPT volume ratio (Rratio), aHD, and mHD.

Left/right volume ratio was used to compare the left/right volumes derived from these two LPT segmentations; these parameters can be re-formulated as the ratio of RtoW and LtoW, which calculate right and left LPT to entire liver volume. LtoW and RtoW are two key parameters in dosimetry and therapy planning in SIRT. They are used in most of the activity calculation methods (BSA, partition method) to split total activity into the right and left lobe activity: $$\documentclass[12pt]{minimal}
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Volume difference is the liver volume which is assigned to different lobes by CBCT and standard venous anatomical lobe segmentation, normalized by total liver volume. Similar to the liver segmentation evaluation, aHD and mHD are based on distances between the (operator-defined) planes that are used to separate the LPTs. $$\documentclass[12pt]{minimal}
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where *L*~*A*~ and *R*~*A*~ are the left and right LPT volumes defined by the expert on CBCT images, respectively, and *L*~*B*~ and *R*~*B*~ are the left and right LPT volumes defined on the CT images. S(A) denotes the set of voxels in the segmented liver which lie on the plane which separates the left and right LPTs. The LPT segmentation in S(A) was derived from the the contrast CBCT-based segmentation. S(B) is defined in the same way for lobe segmentation based on anatomy (on CT).

### Role of perfusion territory segmentation in dosimetry {#Sec17}

In the SIRT workflow, the volumes of the right and left LPTs are used to compute the activities that should be administered to each of the lobes \[[@CR13], [@CR70], [@CR71]\]. Our hypothesis is that CBCT contains more accurate information about perfusion territories than CT which only contains anatomical landmarks to distinguish the left and right liver lobes and is based on the venous anatomy (which sometimes is different from the arterial perfusion territories). To estimate the impact of using standard venous anatomical lobe segmentation on CT instead of LPT segmentation on CBCT, a simulation was performed:

First, the injected activity for each LPT was calculated by using the non-compartmental partition method \[[@CR83]\] and lobe segmentations based on anatomical landmarks (current clinical workflow): $$\documentclass[12pt]{minimal}
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                \begin{document} $$ {\begin{aligned} \text{IA}_{\text{partition}} (\text{LPT}) [\text{GBq}] = \frac{D_{\text{liver}}[\text{Gy}]\times{\text{CT-based lobe mass [kg]} }}{49.380\left[\nicefrac{\text{Gykg}}{\text{GBq}}\right]} \end{aligned}}  $$ \end{document}$$

where *D*~liver~ is the desired mean dose to the total liver and 40 Gy was used based on the algorithm by the Gil-Alzugaray et al. study \[[@CR73]\]. In our calculation, lobe volume was converted to lobe mass by using 1.03g/c*m*^3^ as the liver density \[[@CR83]\].

Then, a second partition dosimetry was performed to evaluate the absorbed dose for the corresponding injected activity in each LPT by using CBCT-based lobe segmentation results to calculate actual mean absorbed dose (unit: Gy) in each lobe by assuming CBCT-based lobe segmentation as the ground truth: $$\documentclass[12pt]{minimal}
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                \begin{document} $$  D_{\text{LPT}} [Gy]= \frac{49.380 \left[\nicefrac{\text{Gykg}}{\text{GBq}}\right] \times{\text{IA}_{\text{partition}} (\text{LPT}) [\text{GBq}]}}{\text{CBCT-based lobe mass [kg]}}  $$ \end{document}$$

The impact of using CBCT instead of anatomical LPT segmentations is then assessed by computing the difference of *D*~LPT~ of Eq. [7](#Equ7){ref-type=""} from the intended dose of 40 Gy.

Results {#Sec18}
=======

Evaluation of registration methodology {#Sec19}
--------------------------------------

**Expert evaluation:** The registration of CT~FDG~ to CT~MAA~ was reviewed by the nuclear medicine expert (CMD). The results for the registration evaluation are shown in Fig. [6](#Fig6){ref-type="fig"} and demonstrate that the proposed method for registering CT~FDG~ to CT~MAA~ was near perfect for 5 patients (29%) and with little misalignment for 11 patients (65%), with moderate misalignment for one patient (6%), and none of the cases were scored as "pronounced misalignment" or "major misalignment". Figure [7](#Fig7){ref-type="fig"} shows an example of little misalignment for CBCT and CT~FDG~ to MAA non-rigid registration. Fig. 6Expert Likert score for CT~FDG~ to CT~MAA~ registration Fig. 7An example (patient ID BI02 from training set in our database) of mis-registration for CT~FDG~ and CBCT to CT~MAA~ non-rigid registration (Likert score for this patient is "little misalignment," contours come from automatic liver segmentation and red arrows point to mis-registration area. **a** Reference image (CT~MAA~), **b** deformed CT~FDG~, **c** deformed meta-CBCTs

**Local volume change:** The Jacobian determinant for non-rigid registration deformation is a parameter which shows the local volume change. A Jacobian determinant equal to 1 corresponds to no volume change, greater than 1 corresponds to a local dilation, and less than 1 corresponds to a local contraction. Negative Jacobian shows up where the deformation is locally non-revertible. Figure [8](#Fig8){ref-type="fig"} shows a transaxial and coronal slice of the non-rigid registration with Jacobian determinant distribution for a patient. Fig. 8An example (patient ID BI04 from training set in our database) of transaxial and coronal view of non-rigid registration evaluation for a patient with Likert score of "little misalignment," the statistics \[min, Q1, median, Q3, maximim\] of the Jacobian over all liver voxels, eroded liver, and excluded liver for this patient are \[0.42, 0.82, 0.89, 0.97, 1.74\], \[0.58, 0.83, 0.88, 0.96, 1.45\], and \[0.42, 0.82, 0.90, 0.99, 1.74\], respectively, (red contours are from the excluded liver and eroded liver---see **b**): **a** reference image CT~MAA~, **b** excluded and eroded liver: eroded liver is manual liver segmentation eroded by 10 mm and excluded liver is the subtraction of excluded liver from liver **c** and **d** results of non-rigid registration (CT~FDG~ to CT~MAA~) and the deformation grid and **e** Jacobian determinant of the non-rigid registration: blue, local dilation; red, local contraction; and white, no local volume change

Figure [9](#Fig9){ref-type="fig"} shows the statistics of the Jacobian determinant. The median of the Jacobian determinant of liver voxels ranged from 0.81 to 1.05 for all cases, while the median range for eroded liver and exclude liver voxels were very similar (\[0.79,1.07\] and \[0.83,1.05\] respectively). But higher local contraction occurred in excluded liver (minimum of Jacobian ranged from 0.36 to 0.67) compare to eroded liver by minimum Jacobian range of \[0.45,0.69\]. Also, the excluded liver had higher local dilation (maximum of Jacobian ranged from 1.47 to 1.78) compared to the eroded liver which had a maximum Jacobian range of \[1.25,1.59\]. Fig. 9First, second, and third interquartile range, minimum, maximum, and mean of for Jacobian determinant for the liver, eroded liver (liver eroded with 10 mm), and liver excluded (subtraction of eroded liver of liver), this measure shows the local dilation (Jacobian greater than 1), local contraction (Jacobian less than 1), and no local volume change (Jacobian 1) for each voxel for liver voxels, core of the liver, and border of the liver

Liver segmentation comparison and validation {#Sec22}
--------------------------------------------

Our semi-automatic liver segmentation used joint region growing by using information from CT~MAA~, CT~FDG~, and ^18^F-FDG PET. The results of the joint region growing were manually adjusted for all the patients. The initial liver segmentation (seed for region growing) took up to 4 min (median =3 min) and final adjustment took up to 6 min (median = 4 min). Figure [10](#Fig10){ref-type="fig"} illustrates the performance of the total liver segmentation by 4 volumetric accuracy metrics (dice, TPR, PPV, and RV) for all training and test cases. Statistics of these metrics for all patients (test cases and training set) are summarized in Table [2](#Tab2){ref-type="table"}. Median and mean of the dice coefficient were both 0.92 showing very similar liver segmentation by both methods with very narrow interquartile range. TPR and PPV had a median of 0.94 and 0.92 which means on average 94% of the liver, which was segmented with manual segmentation, was also segmented with automatic segmentation, and 92% of automatic segmented liver volume was also segmented by the manual segmentation. RV is a very important parameter for injected activity planning. If the partition method or BSA method is used for calculating injected activity, the volume of the liver plays an important role. So, the ratio between the volumes is a key parameter in liver segmentation for SIRT. Our analysis shows that the median (i.e., 1.03) was very close to 1. The accuracy of the segmentation is important if one wishes to use small scale dosimetry (e.g., voxel level dosimetry). The average (aHD) and maximum (mHD) distance between the liver surfaces obtained with the semi-automated method and by the expert were 3 and 22 mm, respectively. Fig. 10Volumetric evaluation of liver and lobe segmentation for training and test cases. Dice coefficient, true positive ratio, positive protective value, and relative volume for liver manual and automatic segmentation and ratio between right/left lobe volumes for two different lobe segmentation procedures (anatomical lobe segmentation on CT and LPT segmentation on CBCT) Table 2Evaluation of total liver segmentation for all cases (test set and training set were pooled together); dice coefficient, true positive ratio, positive protective value, relative volume, and maximum and average of Hausdorff distances for manual and automatic liver segmentationDiceTPRPPVRVmHD (mm)aHD (mm)Minimum0.870.850.840.8816.932.09Q10.910.910.890.9820.542.51Median (Q2)0.920.940.921.0322.393.04Q30.930.960.941.0830.623.16Maximum0.940.990.961.1747.264.23Average0.920.940.921.0322.393.04

### Impact of using the CBCT images instead of the CT image for defining LPT {#Sec23}

Results for the volumetric comparison of the two different lobe segmentation procedures for the test and training sets are illustrated in Figs. [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, and [12](#Fig12){ref-type="fig"}, more detailed results for all 17 cases (10 test and 7 training cases) can be found in Table [3](#Tab3){ref-type="table"}. Figure [13](#Fig13){ref-type="fig"} shows an example with a large area of disagreement between CBCT- and CT-based LPT segmentation. In this particular case, a tumor was segmented in different LPTs by each of the two LPT segmentation methods. Fig. 11Outline maximum and average Hausdorff distance measures (mHD and aHD) between manual and automatic liver segmentation and two different lobe separation planes (on CT and on CBCT) for training and test cases Fig. 12Volume difference parameter. The liver volume which was assigned to different lobes by standard venous anatomical (using CT) and perfusion (on CBCT) lobe segmentation for both training and test cases Fig. 13An example (patient ID BI02 from training set in our database) of **a** transaxial view of early and late CBCTs, **b** the ^18^F-FDG PET/CT images, as well as, **c** CBCT/CT-based LPT segmentation and tumor segmentation (from ^18^F-FDG PET). In this slice, the tumor was segmented in different lobes by the two methods. Comparing the CBCT- and CT-based lobe segmentation for this patient showed that 10% of the liver volume was assigned to different lobes (Vdiff), the ratio of "right lobe to entire liver volume ratio" for these two methods (Rratio) was 1.08 and the same parameter for the left lobe (Lratio) was 0.82. Furthermore, the average and maximum distance between lobe separation planes by these two methods (aHD and mHD) were 2.74 and 16.94 mm. Dosimetry simulation showed that a mean absorbed dose to the left and right lobe when using CBCT-based lobe segmentation were 19 and 46 Gy respectively, when we aimed at delivering 40 Gy to each lobe using the CT-based LPT segmentation Table 3Evaluation of lobe segmentation for all cases (test set and training set); volume difference, right lobe volume ratio, left lobe volume ratio, and maximum and average of Hausdorff distance for CT- and CBCT-based lobe segmentationVdiffRratioLratiomHD (mm)aHD (mm)Minimum0.020.860.4818.014.69Q10.050.980.8430.1310.31Median (Q2)0.081.020.9545.8014.18Q30.111.081.0656.9116.97Maximum0.141.221.48138.1640.08Average0.081.020.9748.0015.10

Surface distances are also provided in Table [3](#Tab3){ref-type="table"} and Fig. [11](#Fig11){ref-type="fig"}.

Median of Vdiff (area of disagreement for lobe segmentation) was 8% of the liver volume, and in some cases, it was as high as 14%. This is an important source of error for high level dosimetry (e.g., compartmental partition model and voxel level dosimetry) when there is a tumor in this disagreement area (see Fig. [13](#Fig13){ref-type="fig"}).

The median of the ratio between left/right lobe ratio index that has a direct effect on splitting the total prescribed injected activity in all prescription methods was near 1 (1.02 and 0.95 for Rratio and Lratio, respectively), but the deviation from 1 was very high, and for some cases, this deviation was up to 48% (see "[Role of perfusion territory segmentation in dosimetry](#Sec24){ref-type="sec"}" section).

The median of aHD and mHD between the two separating planes for the all patients were 3.04 and 22.39 mm, respectively. This shows a possible error for compartmental partition model and voxel level dosimetry because the same tumor can be assigned to a different liver perfusion territory, depending on the procedure used to segment the liver lobes. This would be very problematic for using the dosimetric result either for finding injected activity or post-treatment verification (see Fig. [13](#Fig13){ref-type="fig"}).

Role of perfusion territory segmentation in dosimetry {#Sec24}
-----------------------------------------------------

For analyzing the effect of using the standard venous anatomical lobe definitions instead of the perfusion territories, a simulation was designed to calculate the absorbed dose in each CBCT-based LPT. Our dosimetry calculations showed that when we aim at delivering 40 Gy to the total liver, a median absorbed dose to the right CBCT-based LPT (using the standard venous anatomical lobe segmentation) was 40.8 with a \[min, max\] deviation of \[--5.9, 8.8\] Gy from 40 Gy. For the left lobe, the deviation was wider, and the median absorbed dose was 38.1 Gy; however, the range of deviation was \[--20.7, 19.1\] Gy. Figure [14](#Fig14){ref-type="fig"} shows the results of the absorbed dose in the left and right LPTs (Fig. [13](#Fig13){ref-type="fig"} shows a transaxial view slice of a LPT segmentations). Fig. 14Dosimetry simulation result in each lobe when we aimed at 40 Gy for each lobe based on standard venous anatomy delineation and using CBCT-based LPT segmentation and injected activity calculated by the partition method

Discussion {#Sec25}
==========

Our aim was the development of a semi-automatic procedure for registration and segmentation of all the images acquired in the planning of and during SIRT The tool aligns all available images and provides semi-automatic delineation of the total liver, the liver perfusion territories, and the tumour lesions. The total liver is delineated on PET/CT, the perfusion territories on CBCT, and the tumours on ^18^F-FDG PET/CT. Since no ground truth is available, we have evaluated the semi-automated segmentations by comparison to manual expert segmentations and the registrations were evaluated visually by an expert.

Validation of registration {#Sec26}
--------------------------

Because in our method, we used information from all images to segment different VOIs, the accuracy of registration plays an important role. Also the alignment between the ^99m^Tc-MAA SPECT/CT images and the final segmentation highly affect the dose volume histograms and dosimetry analysis.

The assumption is that in our registration algorithm, the deformations inside the liver were more driven by the liver boundary registration than by correct alignment of inner liver structures. For that reason, we maximized the rigidity inside the liver, in the hypothesis that this better approximates the true deformation.

Maximizing the rigidity of non-rigid registration, also, favors local volume preservation in liver voxels. A Jacobian determinant was used to estimate this local volume change due to non-rigid registration. The result of Jacobian determinant analysis showed relatively small volume change for central liver voxels. Bigger volume changes (either contraction or dilation) were observed near the border of the liver.

Sometimes these assumptions (high rigidity of liver movement and lack of local volume change of the liver) are questionable because of some small non-rigid deformation of the liver and because of anatomical liver changes over time, but still it seems reasonable to limit the non-rigidity of liver registration. In those cases, our parameter selection may contribute to mis-registration errors. Another possible source of error in registration could be the artifacts in the CT images (e.g., streak artifacts or photon starvation due to elbows inside field-of-view) and non-rigid liver deformation due to patient position. Likert scoring results for registration accuracy showed that this mis-registration was not crucial in most of the cases of CT~FDG~ to CT~MAA~ registration.

In clinical routine, the Jacobian can be used as a quality control step to warn physicians about possible registration problems. Our visual investigation showed that the upper and lower part of the liver were the areas with deviation from Jacobian determinant of 1 for most of the cases. In general, the results suggest that the registration error was low compared to other sources of error in SIRT dosimetry, but in areas with mismatch between ^18^F-FDG PET and ^99m^Tc-MAA SPECT, we suggest to look more carefully into registration deformation to avoid underestimation of tumor dose/activity and overestimation of healthy tissue dose/activity.

One of the limitations of this study is that during MAA SPECT/CT and ^18^F-FDG-PET/CT, shallow breathing was allowed and breathing motion is not corrected. It has been shown that respiratory motion can impose a large error into final dosimetry results. Bastiaannet et al. report 90 to 66% decrease in activity recovery and tumor-to-normal ratios because of respiratory motion in a series of SPECT/CT Monte Carlo simulation using digital XCAT phantoms \[[@CR74]\].

Validation of liver segmentation {#Sec27}
--------------------------------

Liver segmentation is very important for dosimetry-based prescription of activity. Dice, TPR, and PPV parameters showed a high similarity between our semi-automatic segmentation results and manual liver segmentation by an expert, which is used in clinical routine. A comparison between our liver segmentation results and the accurate methods on liver segmentation reviewed by Moghbel et al. \[[@CR40]\] shows that our Dice metric (mean = 0.92) is similar to what is reported in previous published liver segmentation algorithms (\[0.91,0.94\]), and our relative volume metric (mean =1.03) is comparable with the result of the most accurate algorithms ($\documentclass[12pt]{minimal}
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These results show that our semi-automatic liver segmentation was comparable with manual liver segmentation by an expert. Because this segmentation method is applied to a multi-modal image (PET and CT), it uses more information, and therefore, its segmentations could even be slightly superior. This will be further investigated in the future.

Validation of the lobe segmentation {#Sec28}
-----------------------------------

In standard clinical routine, the lobe segmentation is done on a CT image based on anatomical landmarks, predominately based on venous structures. Here, we studied an alternative approach, where the lobes were segmented on contrast-enhanced CBCT images. A graphical user interface was developed to cut the liver on CBCT and CT by drawing just a few separation lines on different transverse slices, it usually takes less than a minute for the expert for each case.

In several cases, the expert separated the liver differently into lobes, depending on whether anatomical CT images or perfusion CBCT images were being used. Evaluation of these two different lobe segmentation procedures suggested that there was a relatively large area in the center of the liver where the standard venous anatomical lobe segmentation on CT differed from the perfusion-based segmentation on CBCT. This can cause a large error for total administered activity distribution in bilobar treatment and in dosimetry. If there is a tumor in this disagreement area, there is a risk of assigning the tumor to the wrong perfusion territory, which could lead to serious underdosing of the tumor (see Fig. [13](#Fig13){ref-type="fig"}).

Contribution of lobe segmentation methodology in dosimetry uncertainty {#Sec29}
----------------------------------------------------------------------

LtoW and RtoW---ratio between left/right to entire liver volume---(which is very important for dividing the total injected activity for left and right lobe) had a median of 0.95 (range \[0.48, 1.48\]) and 1.02 (range \[0.86, 1.22\]), respectively. The volume ratio of the left LPT to the entire liver had a wider range than right to entire because the left lobe is generally smaller than the right lobe and is more sensitive to mis-segmentation. It showed that the left lobe suffered more from under/over-treatment or under/over-irradiation by using the standard venous anatomical lobe segmentation as an estimate of the LPT. In our dosimetric setting, this under-treatment could be up to 21 Gy for the left lobe and 5 Gy for the right lobe. On the other hand, over-irradiation of the left lobe was up to 19 and 9 Gy for the left and right lobe, respectively.

Tumour segmentation {#Sec30}
-------------------

In this study, we have focused on ^18^F-FDG-avid tumors that can be delineated by thresholding the ^18^F-FDG PET images. In this study, an adaptive threshold method was used for tumor segmentation which uses a tumor-specific threshold level by considering the SUV~max~ and background SUV for each tumor separately. Because thresholding the ^18^F-FDG-images is straightforward and the same as the method used by experts to delineate the lesions, we have not attempted to further evaluate the tumor delineation.

Conclusion {#Sec31}
==========

A multi-modal image analysis approach was developed to obtain a personalized liver map (liver, perfusion territories, and tumor segmentation) from the pre-treatment ^99m^Tc-MAA SPECT/CT, ^18^F-FDG PET/CT, and CBCT images. The analysis showed that liver segmentation was comparable with manual segmentation by an expert. Liver perfusion territory segmentation by using CBCT instead of using CT and anatomical features showed to improve segmentation; the results showed a relatively high difference in volumetric parameters that are very important for SIRT in clinical routine.

Our results were based on 7 cases for optimizing and 10 test cases. Extending the number of patients can help us to evaluate our routine in clinical practice.

This procedure can be used in the future to provide semi-automatic voxel level fractional uptake predictions based on the ^99m^Tc-MAA SPECT/CT. By using this workflow, various dosimetry reports can be computed which can be used to evaluate and improve the safety and effectiveness of SIRT. This method can be used in the future for finding the injected activity more accurately by using either dosimetric methods (partition, voxel level dosimetry) or non-dosimetric methods (BSA, SIRFLOX look-up table \[[@CR84]\]).

This procedure was designed for patients with ^18^F-FDG-avid tumors, but in the future, it can be extended to using magnetic resonance (MR) images instead of PET/CT images in patients with non ^18^F-FDG-avid tumors such as hepatocellular carcinoma.

Appendix: Patient information {#Sec32}
=============================

###### 

Patient characteristics

  Characteristics                                                               All cases                Training set             Test set
  ----------------------------------------------------------------------------- ------------------------ ------------------------ ------------------------
  Patient information                                                                                                             
  Sex (female/male)                                                             6/11                     3/4                      3/7
  Age in years, median \[range\]                                                60.5 \[32.9, 72.3\]      60.6 \[32.9, 72.3\]      58.2 \[36.2, 69.5\]
  Height in meter, median \[range\]                                             175 \[160, 193\]         174 \[163, 186\]         178 \[160, 193\]
  Weight in kg, median \[range\]                                                81 \[61, 123\]           79 \[71, 100\]           84 \[61,123\]
  Tumor cell type, n (%)                                                                                                          
  Colorectal cancer                                                             7 (41%)                  1 (14%)                  6 (60%)
  Breast cancer                                                                 2 (12%)                  2 (29%)                  0 (0%)
  Melanoma cancer                                                               2 (12%)                  2 (29%)                  0 (0%)
  Esophageal cancer                                                             2 (12%)                  1 (14%)                  1 (10%)
  HCC                                                                           1 (6%)                   1 (14%)                  0 (0%)
  Neuroendocrine tumor                                                          1 (6%)                   0 (0%)                   1 (10%)
  Colon cancer                                                                  1 (6%)                   0 (0%)                   1 (10%)
  Cholangiocellular                                                             1 (6%)                   0 (0%)                   1 (10%)
  Volumes from prescription sheet (cc), median \[range\]                                                                          
  Total liver (WL)                                                              1892 \[1268, 3127\]      1878 \[1663, 2721\]      1907 \[1268, 3127\]
  Total liver (L-LPT)                                                           448 \[215, 1197\]        390 \[251, 1050\]        514 \[215, 1197\]
  Total liver (R-LPT)                                                           1496 \[677, 1930\]       1330 \[1223, 1839\]      1533 \[677, 1930\]
  Healthy liver (WL)                                                            1700 \[1218, 2988\]      1700 \[1513, 2528\]      1694 \[1218, 2988\]
  Healthy liver (L-LPT)                                                         390 \[135, 1115\]        390 \[201, 1041\]        395 \[135, 1115\]
  Healthy liver (R-LPT)                                                         1319 \[700, 1873\]       1241 \[1184, 1612\]      1344 \[700, 1873\]
  Tumor (WL)                                                                    150 \[7, 643\]           150 \[28, 494\]          153 \[7, 643\]
  Tumor (L-LPT)                                                                 36 \[0, 312\]            18 \[0, 109\]            51 \[0, 312\]
  Tumor (R-LPT)                                                                 130 \[7, 479\]           146 \[10, 479\]          93 \[7, 331\]
  Clinical information from prescription sheet (%), median \[range\]                                                              
  Tumor involvement (WL)                                                        7.1 \[0.4, 27.8\]        8.5 \[1.5, 24.2\]        5.7 \[0.4, 27.8\]
  Tumor involvement (L-LPT)                                                     6.9 \[0.0, 47.3\]        4.8 \[0.0, 28.7\]        8.7 \[0.0, 47.3\]
  Tumor involvement (R-LPT)                                                     8.6 \[0.8, 27.7\]        11.0 \[0.8, 27.7\]       6.5 \[1.1, 20.0\]
  L-LPT to WL volume                                                            25 \[11, 60\]            23 \[12, 39\]            27 \[11, 60\]
  Lung shunt fraction (LSF)                                                     6.4 \[3.8, 8.5\]         7.4 \[3.8, 8.2\]         5.8 \[3.9, 8.5\]
  Day differences between different studies and SIRT (days), median \[range\]                                                     
  ^18^F-FDG and SIRT                                                            20 \[3, 58\]             35 \[3, 58\]             16 \[6, 40\]
  ^99m^Tc-MAA and SIRT                                                          21 \[15, 41\]            21 \[15, 32\]            21 \[15, 41\]
  Prescription                                                                                                                    
  IA calculation method                                                                                                           
  BSA method, n (%)                                                             14 (82%)                 7 (100%)                 7 (70%)
  Partition model, n (%)                                                        3 (18%)                  0 (0%)                   3 (30%)
  IA in GBq, median \[range\]                                                                                                     
  WL                                                                            1.850 \[1.268, 2.502\]   1.837 \[1.746, 2.063\]   1.882 \[1.268, 2.502\]
  L-LPT                                                                         0.457 \[0.228, 1.089\]   0.457 \[0.228, 0.724\]   0.469 \[0.248, 1.089\]
  R-LPT                                                                         1.339 \[0.733, 1.783\]   1.339 \[1.113, 1.640\]   1.414 \[1.113, 1.640\]

*WL* whole liver

*L-LPT* left liver perfusion territory

*R-LPT* right liver perfusion territory

Supplementary material: Joint region growing for liver segmentation {#Sec33}
===================================================================

A joint region growing method has been designed to delineate the liver using CT from MAA SPECT/CT, and CT and PET from ^18^F-FDG PET/CT study. The algorithm consisted of the following three steps:

\- Initial liver segmentation: First, we manually segmented the liver in every 15th slice corresponding to 15 mm in the axial direction. The final liver segmentation was done independently in each of these volumes (of 15 slices) by the joint region growing algorithm. The eroded version (*r* = 20 voxels) of the intersection of two neighboring segmentations defined the seed for the joint region growing algorithm, and the dilated (*r* = 20 voxels) union determined the mask of the joint region growing algorithm. In the joint region growing algorithm, a voxel (*μ*~*j*~) within the selected mask was considered as the liver if its intensity satisfies: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document} $$ \forall i:\left|\mu_{j}-\mu^{i}\right| \le 2\times{\sigma^{i}},i=\text{CT}_{\text{MAA}},\text{CT}_{\text{FDG}},\text{PET}  $$ \end{document}$$

where *μ*^*i*^ and *σ*^*i*^ are the mean and standard deviation of the segmented voxels in image *i* in the previous step of region growing (see Fig. [3](#Fig3){ref-type="fig"}).

\- Second region growing: The segmentation from the previous step was used as the seed for the second region growing. In this step, the dilated version of the resulting VOI by radius 20 voxels was used as the mask. In the second joint region growing algorithm, a voxel (*μ*~*j*~) within the selected mask was considered as the liver if its intensity satisfies: $$\documentclass[12pt]{minimal}
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                \begin{document} $$ \forall i:k_{1}^{i}\times{\sigma^{i}} \le \mu_{j}-\mu^{i} \le k_{2}^{i}\times{\sigma^{i}},i=\text{CT}_{\text{MAA}},\text{CT}_{\text{FDG}},\text{PET}  $$ \end{document}$$

where *μ*^*i*^ and *σ*^*i*^ are the mean and standard deviation of the segmented voxels in image *i* in the previous step of region growing. $\documentclass[12pt]{minimal}
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                \begin{document}$\left (k_{1}^{i},k_{2}^{i}\right)$\end{document}$ was set to (−2.5,2), (−2.5,2), and (−2,*∞*) for *i*=CT~MAA~,CT~FDG~,andPET, respectively, also *μ*~*j*~ was restricted to be below 2.5 standardized uptake value (SUV) for *i*=PET.

\- Adjustment: Finally, the resulting VOIs were adjusted manually and closing and opening with 3 mm were applied.

^18^F-FDG

:   Fluorine-18 fluorodeoxyglucose

aHD

:   Average hausdorff distance

BSA

:   Body surface area

CBCT

:   Cone beam CT

CT

:   Computed tomography

HCC

:   Hepatocellular carcinoma

LPT

:   Liver perfusion territory

Lratio

:   Left LPT volume ratio

LtoW

:   Left LPT to entire liver volume

MAA

:   Macro-aggregated albumin

mCRC

:   Metastatic colorectal cancer

mHD

:   Maximum hausdorff distance

MR

:   Magnetic resonance

OSEM

:   Ordered subset expectation maximization

PET

:   Positron emission tomography

PPV

:   Positive predictive value

RE

:   Radioembolization

Rratio

:   Right LPT volume ratio

RtoW

:   Right LPT to entire liver volume

RV

:   Relative volume

SIRT

:   Selective internal radiation therapy

SPECT

:   Single-photon emission-computed tomography

SUV

:   Standardized uptake value

TARE

:   Transarterial RE

TPR

:   True positive ratio

Vdiff

:   Volume difference

VOI

:   Volume of interest
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